Medicine A, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Am J Med. 2017 Apr;130(4):477-481. doi: 10.1016/j.amjmed.2016.11.022. Epub 2016 Dec 16.
Chills are a complication of patients undergoing hemodialysis. The rate of infection among hemodialysis patients presenting with chills is not well established, and empirical broad-spectrum antibiotics are usually the rule.
We performed a retrospective study aiming to assess the rates of infection and bacteremia in hemodialysis patients presenting with chills. We evaluated risk factors for infection and bacteremia and tested a prediction model for infection.
Overall, 269 hemodialysis patients with a first episode of chills were included. Ninety patients (33.5%) had bacteremia and 162 (60.2%) had an infection. Risk factors for bacteremia in multivariate analysis included fever (odds ratio [OR] 1.6; 95% confidence interval [CI], 1.1-2.3; P = .009) and vascular catheter as dialysis access (OR 6.2; 95% CI, 3.2-12.0, P <.001). Leukocytosis was an additional risk factor in multivariate analysis for any type of infection (OR 1.265; 95% CI, 1.113-1.438; P <.001). Using a prediction model to evaluate patients without obvious source of infection, we found that patients with fistula or graft as their access, without fever, abnormal leukocytes, or hypoalbuminemia, had a low rate (1/17, 6%) of bacteremia.
Hemodialysis patients presenting with chills during dialysis, with or without fever, have high rates (∼60%) of infection. Patients with no obvious source of infection, with fistula or graft as access, presenting without fever, leukocytosis, or hypoalbuminemia have low risk for bacteremia and may be investigated without prompt antibiotic treatment. All other patients should receive antibiotic coverage immediately following a chills episode.
寒战是接受血液透析患者的一种并发症。出现寒战的血液透析患者的感染率尚不清楚,通常采用经验性广谱抗生素治疗。
我们进行了一项回顾性研究,旨在评估出现寒战的血液透析患者的感染和菌血症发生率。我们评估了感染和菌血症的危险因素,并对感染预测模型进行了检验。
共纳入 269 例首次出现寒战的血液透析患者。90 例(33.5%)发生菌血症,162 例(60.2%)发生感染。多变量分析中,发热(比值比[OR] 1.6;95%置信区间[CI],1.1-2.3;P =.009)和血管导管作为透析通路(OR 6.2;95%CI,3.2-12.0,P <.001)是菌血症的独立危险因素。白细胞增多也是任何类型感染的多变量分析中的另一个危险因素(OR 1.265;95%CI,1.113-1.438;P <.001)。使用预测模型评估无明显感染源的患者,我们发现通路为瘘管或移植物,无发热、白细胞异常或低白蛋白血症的患者,菌血症发生率较低(1/17,6%)。
接受血液透析治疗的患者在透析过程中出现寒战,无论是否发热,都有很高的感染率(约 60%)。无明显感染源,通路为瘘管或移植物,无发热、白细胞增多或低白蛋白血症的患者,菌血症风险较低,可能无需立即进行抗生素治疗。所有其他患者在出现寒战后都应立即接受抗生素治疗。